Hypertension Management by Pharmacist Interventions

By HEOR Staff Writer

November 10, 2023

Hypertension Management

The Rising Challenge of Hypertension

Hypertension management, a significant risk factor for cardiovascular and kidney diseases, is a leading cause of preventable death and disability globally. With more than 100 million people affected in the US alone, the healthcare costs associated with hypertension surpassed $130 billion between 2003 and 2014. Despite the availability of affordable medications and lifestyle interventions, blood pressure control rates continue to decline.

Pharmacist Interventions: A New Approach to Hypertension Management

Recent research suggests an innovative solution: pharmacist-led interventions. Pharmacists, who often see patients more frequently than physicians, are well-positioned to screen and manage hypertension. Numerous clinical trials have demonstrated improved hypertension outcomes through pharmacist-led case-finding and prescribing interventions.


A cost-effectiveness analysis of implementing pharmacist prescribing for hypertension management in the US has yielded promising results. The pharmacist intervention was associated with 2100 fewer cases of cardiovascular disease and 8 fewer cases of kidney disease per 10,000 patients. Furthermore, it resulted in overall cost savings of $10,162 per person.

Reference url

Recent Posts

TrumpRx.gov expansion
TrumpRx.gov Expansion: Enhancing Medication Price Transparency and Competition

By João L. Carapinha

May 22, 2026

TrumpRx.gov expansion marks a major step toward greater medication price transparency, as detailed in President Donald J. Trump’s announcement to list more than 600 generic drugs on the platform. Patients can now compare competitive cash prices from Amazon Pharmacy, Cost Plus Drugs, and GoodRx fo...
trastuzumab-deruxtecan reimbursement
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiveness for Advanced Gas...
Zorginstituut Nederland advises against routine trastuzumab-deruxtecan reimbursement for adults with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma after two or more prior therapies, unless price negotiations secure at least a 62 percent reduction. The drug meets scientific s...
Portugal health spending 2025
Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand
Portugal health spending 2025 hit a fresh peak as the country’s publicly funded National Health Service recorded its highest annual outlay on medicines, reaching €4.417 billion according to Infarmed data. This total, already net of industry rebates and contributions, was propelled chiefly by expa...